Peking University Third Hospital

Stories

Innovent's tafolecimab meets primary endpoint as first-line monotherapy

Lead site for the CREDIT-5 trial

Innovent Biologics' tafolecimab cut LDL cholesterol by roughly 65% in a Phase 3 trial of patients who took no other lipid-lowering drug. The CREDIT-5 result is the first late-stage evidence that a Chinese-made PCSK9 antibody works as a stand-alone first-line treatment for high cholesterol.

Updated 3 days ago

China lets clinical medicine students graduate without a thesis

Rule Changes

Ran the first clinical medicine practical-degree defence

On 22 October 2026, a team of government-appointed education advisers released draft rules letting professional master's and doctoral students in clinical medicine graduate with a practical achievement instead of a thesis. A student could now submit an analysis of a special clinical case, or an investigation into a problem facing a medical institution, and defend that instead of a dissertation.

Updated Nov 3